Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
How Stress Affects Your Body
Next
Download to read offline and view in fullscreen.

38

Share

History of antibiotics

Download to read offline

Antimicrobial resistance is one of the most important subjects of the 21st century. With the potential to cause nearly $100 trillion in damage to the world health and economy, the issue of infections untreatable by modern antibiotics is one that leaves many concerned and looking for answers.

What’s even more concerning is the scarce, almost empty antibiotic pipeline. Between 1935 and 1968, there were over 15 new classes of antibiotics developed, since 2000, there have only been 3. We all know why this is the case: antibiotic development is not only risky, it also does not have a viable ROI.

In response, the US government provided the GAIN Act which provide waived fees and market exclusivity. Federal funding awarded through NIAID and BARDA are also available to alleviate the high cost of development, making antibiotic development lucrative and attractive to pharma and biotech.

Private funding agencies such as Wellcome Trust, IMI and ARLG have also come up with plans to provide relief.

But are these enough?

- See more at: http://goo.gl/f2AYmE

Related Audiobooks

Free with a 30 day trial from Scribd

See all

History of antibiotics

  1. 1. r . i wonLb, @ . U u mES|8TANCEC@NGHESS rusrm a A 'JE"I;3‘. !'3 - < -, e Pmlalfi-r| .hl| :'I. r.III. I11d: +trbe Flr. d:l. IIIl'Ii: fiIL: :ln'II‘hI: '|: I. -uhwfiziltdnsimldbrflnnr . .. ... ... ... ... ... ... ... ... ... . . . -[gin l: ':! 'n"l: '.'| | JIH _- 3‘-cl : .-3 V _ ‘ [l_F’fi«E. ‘l'|3'.5'. -E‘! -' HIE'. 'FF. | 5'H'| -|'}"'I'H. |?l'| '|-I'| Ui: |2H'l"I I '"WFInlDIm N 19.1]? .. ... ... ... ... ... ... ... ... .. . ... j ET. -"1E| ."E2!'. '.‘rEi H nae-sis-ice . ?-r. .‘. i|; E=. ri. -§i. 'I I, . _. " i-: Irl. ‘-“.7.‘I‘ Tflugrtkilni-Hindus -W-:1-rs , . . . ‘ '-"""""‘: """""""' K . n‘ d'i‘5E‘J} | rhI: rI: i:hI: h:s; I-'rl: | n- sass Hr‘-E-F3 L! ['E F-TEEE-T-'~l'~'|3 E r. -"L-', ~|! !D. :Tfl I. .. ... ... ... ... ... ... ... ... ... 1553 T§"F}'-.5 '| "'|3l'_| ‘-"E HE E! 5 I.4'. !'i".3 E . -*£H| E'u'E|2‘ .5"-. I.'i" 'II'. . R; -''. ''-. I . -‘Ifl'| '."I '1‘. -’-. FF 'I. -'= - ac: J fflfiS= a 5r'rIi'l| I=nEn: :hl1'-'| :u: I I-fl'«ntIII-l'r'IaI1hfl: i_ mhflufil ‘: __ . . . ... .. ". .-I'| sens ~ : _'pbpI| fit. i'&'I1l: I!i. - d. tI| :cn-‘Id WW-"1.. ... ... -I ififlfl 5:51-‘ I"- fi. h'| :|t-| hh'el. Iq. .I. di: In| i The Werltl Anti-Micmbial Resistance Congress 2015 is bringing all bf the greatest minds in the antimicrobial field tbgether te tackle this very issue. It‘s time be step talking abeut the preblem and start discussing selutiens, which is why we are bringing in Pharma, academia and the gcnrernmerit. Speakers include: David i-Ielnlclr, Vice Michael Dudley, Senibr Melissa Stuandicit. Chief. President. Clinical Vice President bf Antidnfectives Pregram. Derrelepment. Anti- Research and HARD! Infectires. Alrlai-‘ls Develepment and Chief Scientific flrfficer, Thu‘. - Medicines cum; -any : n;rl; ~a1;ea1i its 1’ 1:r. ;n%lr. s‘: eI: ain-.13 .7-_=1~: rii: e:. ~‘: r;ris3i. i;. .,cafre1i[i; e’n§re;3 ‘3?r—ili: i5:iT;3g: ; «. :iIit= %ra. ;r: a~; ::. a*: ‘a‘r. r;ir_? _g%; . @3:= rnn‘n: s1rgfsitIiber’nnn aimtajr rsea*rrarm;7 fin. -,r: .:a_i1.: ::: .-s an: ajns: .re: n:_mn«r:2, ‘~; -.; ~.rifl: .r ‘sill : éii*: ::Eas. <:u. n:~: :'e’rii "s; i!in; e J_L3a§nri. :1i7i»irfii_ij; ma. Pj W@RL“»”3‘~r NTI-MICRQBIA CQNGRESS i“5 fl 9015 ids; Li --uunflnn-Iu---I- . _._—T. . . - . - . g_’ i‘ M _F_I _ 29 —CIc. tb, ber -4 I. _. . .. -. _Q- 1.. '_ r | I- 0- "Ii-ieteil, D. -C. ‘fr . ~n: n:; rr: m/ AMR
  • MDAbayedUllah

    Jul. 1, 2021
  • taranehmousavi

    May. 3, 2019
  • ErinWashowich

    Feb. 16, 2019
  • RebeccaTroeller

    Jan. 18, 2019
  • DavidJeansonne1

    Nov. 13, 2018
  • AlexLucio1

    Nov. 5, 2018
  • DrMichaAbeles

    Oct. 11, 2018
  • lindsayviner

    Aug. 17, 2018
  • DustyParadee

    Aug. 6, 2018
  • gvalenciab

    Feb. 4, 2017
  • CarmeloGimenoTurn

    Dec. 8, 2016
  • NormanCaines1

    Dec. 5, 2016
  • DrMadihaQutbi

    Nov. 7, 2016
  • janukakc

    Oct. 19, 2016
  • Marzlyn

    Jul. 8, 2016
  • TheRealAkansha

    Jun. 22, 2016
  • BevJH

    Mar. 23, 2016
  • indiadentist

    Feb. 18, 2016
  • KishoreCherala

    Jan. 18, 2016
  • fl0r3cita

    Jan. 12, 2016

Antimicrobial resistance is one of the most important subjects of the 21st century. With the potential to cause nearly $100 trillion in damage to the world health and economy, the issue of infections untreatable by modern antibiotics is one that leaves many concerned and looking for answers. What’s even more concerning is the scarce, almost empty antibiotic pipeline. Between 1935 and 1968, there were over 15 new classes of antibiotics developed, since 2000, there have only been 3. We all know why this is the case: antibiotic development is not only risky, it also does not have a viable ROI. In response, the US government provided the GAIN Act which provide waived fees and market exclusivity. Federal funding awarded through NIAID and BARDA are also available to alleviate the high cost of development, making antibiotic development lucrative and attractive to pharma and biotech. Private funding agencies such as Wellcome Trust, IMI and ARLG have also come up with plans to provide relief. But are these enough? - See more at: http://goo.gl/f2AYmE

Views

Total views

7,415

On Slideshare

0

From embeds

0

Number of embeds

484

Actions

Downloads

145

Shares

0

Comments

0

Likes

38

×